Michael Gibney
Senior Editor & Writer | LinkedInMichael Gibney is a senior writer and editor for PharmaVoice. Before that, he covered the pharmaceutical industry as a healthcare reporter for three and a half years at S&P Global Market Intelligence and served as an editor at FiercePharma and FierceBiotech. Besides industry reporting, Michael has also covered science, wildlife and environmental issues as well as local news in Connecticut and Montana. A graduate of Bucknell University and the University of Missouri Journalism School, he is based in the Washington, D.C., area where you’ll find him hiking with two retired racing greyhounds, finding local breweries and grilling in the backyard.
113 articles by Michael Gibney
-
Do humans have a place in pharma’s AI future?
Sept. 26, 2023 -
As the opioid crisis seethes, a long-lasting treatment could offer new ammunition
Sept. 21, 2023 -
Moderna’s bold five-year plan reflects Big Pharma tradition of ‘Will they deliver?’
Sept. 15, 2023 -
In the renal space, innovation could tackle health disparities. But the system doesn’t reward it.
Sept. 14, 2023 -
‘Not all rainbows and unicorns’ — a former CEO dishes on his rocky biotech ride
Sept. 7, 2023 -
Finding the right flu vaccine is hard. Getting people to take it is harder.
Aug. 30, 2023 -
‘We need to do better:’ A biotech CEO on standing apart from the crowd
Aug. 29, 2023 -
‘Eris’ and other new COVID strains accelerate vaccine push from Pfizer, Moderna, Novavax
Aug. 24, 2023 -
Henrietta Lacks’ immortal cells put biopharma profits under a microscope
Aug. 23, 2023 -
How an AstraZeneca exec is leading the charge in the next immuno-oncology era
Aug. 17, 2023 -
Biogen’s Reata acquisition reflects biopharma’s inevitable M&A, IPO return to growth
Aug. 10, 2023 -
In the era of blockbuster obesity drugs, a personalized approach could boost outcomes
Aug. 8, 2023 -
New Alzheimer’s treatments are the tip of the iceberg in a long-stymied area of medicine
Aug. 3, 2023 -
How CymaBay overcame a NASH failure for another shot at liver disease success
Aug. 2, 2023 -
Big Pharma CEOs get candid about pricing and M&A
July 28, 2023 -
For Merck, understanding maternal mortality is the first step toward equity
July 25, 2023 -
Google for genes? This AI company aims to curate the entire human genome.
July 20, 2023 -
As biologics boom, here’s how manufacturers are keeping up
July 19, 2023 -
Novo’s workhorse Ozempic could shine in new areas
July 13, 2023 -
Merck’s New Jersey campus is getting a biotech makeover
July 11, 2023 -
Following FDA’s full approval of Leqembi, here’s what else is in the Alzheimer’s pipeline
July 7, 2023 -
A pharma summer — how leaders unwind and recharge their teams in the warmer months
June 30, 2023 -
Intercept’s NASH retreat is the latest setback for a challenging liver disease
June 27, 2023 -
DIA’s chief exec is on a mission to grow its footprint across healthcare
June 22, 2023 -
AI has secured a footing in drug discovery. Where does it go from here?
June 20, 2023